Niklas Mattsson
Breast cancer gene patents once again found valid by US appeals court
By Niklas Mattsson | Posted on August 23, 2012
In the “Myriad case” an ongoing legal battle with many twists and turns, the Court of Appeals for the Federal Circuit, CAFC, has decided to once again uphold patent claims covering isolated human genes BRCA1 and BRCA2, owned at least partly by Myriad Genetics Inc in Utah, USA. The patent claims were initially invalidated in...
Tags: gene patents, USA
Focus on China
By Niklas Mattsson | Posted on November 18, 2011
The fact that China is growing in importance is well known. To Awapatent, this growth is visible in our day-to-day work, both from the questions we get about IP in China from our European clients, and from the growing demand for our services as a European firm for Chinese clients. Naturally, we make it a...
Supplementary protection for combination products heading for setback at the CJ of the EU
By Niklas Mattsson | Posted on July 14, 2011
Supplementary protection for combination products heading for setback at the Court of Justice of the EU On 13 July 2011, the opinion of the Advocate General (AG) was released in the consolidated cases C-322/10 and C-422/10, “Medeva” and “Georgetown” respectively, concerning supplementary protection certificates (SPCs) for combination vaccines. In her opinion, the AG recommends the...
Tags: CJ, EU, Medication, SPC
Most comprehensive patent reform in almost 60 years approved by US senate
By Niklas Mattsson | Posted on March 11, 2011
Most comprehensive patent reform in almost 60 years approved by US senate Historic breakthrough as USA gets to grips with “first-to-invent”, the enormous backlog of patent applications and simplifying procedures for filing patents in the USA. On Tuesday 8 March 2011, the US Senate voted to approve the nation’s most comprehensive patent reform since 1952,...
BRCA patents in Europe
By Niklas Mattsson | Posted on April 1, 2010
An ongoing lawsuit in the US has attracted a lot of attention worldwide. The American Civil Liberties Union has, together with other parties, sued the US Patent and Trademark Office, Myriad Genetics and others. On Monday 29 March 2010, a judge in a federal District Court in New York ruled that the “Myriad patents” in...
Controversial gene patents finally decided by the EPO
By Niklas Mattsson | Posted on November 27, 2008
During the last decade, the debate in Europe regarding the patentability of human gene inventions has been heavily influenced by “the Myriad case”, concerning patent applications by Myriad Genetics Inc (and others) that relate to the breast cancer susceptibility genes BRCA1 and BRCA2. Through two decisions spaced less than a week apart, the European Patent...
Tags: EPO, gene patents
USPTO will not give up
By Niklas Mattsson | Posted on June 10, 2008
Last fall, the US Patent and Trademark Office, USPTO, announced that they would make drastic changes in the rules concerning patent applications. Briefly, the USPTO rules mean that the applicant’s rights to file different forms of continuation applications are severely limited. The rules were meant to become effective on 1 November 2007. Tons of companies...
Tags: USPTO
Recent contributors
Partner, European Patent Attorney
Senior Associate, Attorney at Law
Partner, Attorney at Law, Group Vice President
Partner, Attorney at Law, Business Area Manager
Senior Counsel, European Patent Attorney
